Net income of Hainan Honz Pharmaceutical drops sharply after 7 deaths
Hainan Honz Pharmaceutical (SHE: 300086) announced its net income for the first half of 2011 will fall around 50%.
The company has watched its stock price drop precipitously after its major product, Ruizhiqing, has been blamed for as many as seven deaths.
Recently, the SFDA prohibited the use of the drug in children under 12. The drug is thought to cause liver damage and has been banned in many of the countries in which it was approved.
This site contains materials from other clearly stated media sources for the purpose of discussion stimulation and content enrichment among our members only.
Whatsonsanya.com does not necessarily endorse their views or the accuracy of their content. For copyright infringement issues please contact firstname.lastname@example.org